본문 바로가기
KERD
논문KCI 등재

Impact of diabetes, obesity, and dyslipidemia on the risk of hepatocellular carcinoma in patients with chronic liver diseases

Hwang Sik Shin|Baek Gyu Jun|Sang-Wook Yi
대한간학회 (The korean Association for the Study of the Liver)|2022.10|Clinical and Molecular Hepatology|제28권 제4호|pp. 773-789

1

조회

0

다운로드

4

인용

0

참고문헌

키워드

ObesityDiabetes mellitusHepatocellular carcinomaDyslipidemias

초록

Despite the increasing prevalence of metabolic disorders, the potential effects of metabolic factors on hepatocellular carcinoma (HCC) development in individuals with chronic liver diseases (CLDs) are not well understood. For a metabolic factor to be identified as a risk factor for HCC in patients with CLDs, such as hepatitis B virus (HBV) and hepatitis C virus (HCV) infection, there should be a strong synergistic interaction between the carcinogenic mechanisms of the metabolic factor and the CLD itself. This review aims to comprehensively summarize the published data on the relationship between metabolic factors such as diabetes mellitus (DM), obesity, and blood lipids and the risk of HCC in patients with CLDs. DM consistently increases the risk of HCC in patients with CLD. When associated with DM, the risk of HCC seems to be highest in HCV and non-alcoholic fatty liver disease (NAFLD), followed by alcoholic liver disease (ALD) and HBV. Obesity may increase the risk of HCC. Among CLDs, the evidence is relatively consistent and clear for ALD, while clear evidence is limited in other CLDs including HBV, HCV, and NAFLD. Total cholesterol, potentially low-density lipoprotein cholesterol and triglyceride, seems to have strong inverse associations with HCC in individuals with CLDs. Despite evidence from observational studies, statins had no effect in preventing HCC in randomized controlled trials. Whether statins have a preventive effect against HCC is unclear. A better understanding and management of metabolic factors may be beneficial to reduce the risk of HCC in patients with CLDs.

Abstract

Despite the increasing prevalence of metabolic disorders, the potential effects of metabolic factors on hepatocellular carcinoma (HCC) development in individuals with chronic liver diseases (CLDs) are not well understood. For a metabolic factor to be identified as a risk factor for HCC in patients with CLDs, such as hepatitis B virus (HBV) and hepatitis C virus (HCV) infection, there should be a strong synergistic interaction between the carcinogenic mechanisms of the metabolic factor and the CLD itself. This review aims to comprehensively summarize the published data on the relationship between metabolic factors such as diabetes mellitus (DM), obesity, and blood lipids and the risk of HCC in patients with CLDs. DM consistently increases the risk of HCC in patients with CLD. When associated with DM, the risk of HCC seems to be highest in HCV and non-alcoholic fatty liver disease (NAFLD), followed by alcoholic liver disease (ALD) and HBV. Obesity may increase the risk of HCC. Among CLDs, the evidence is relatively consistent and clear for ALD, while clear evidence is limited in other CLDs including HBV, HCV, and NAFLD. Total cholesterol, potentially low-density lipoprotein cholesterol and triglyceride, seems to have strong inverse associations with HCC in individuals with CLDs. Despite evidence from observational studies, statins had no effect in preventing HCC in randomized controlled trials. Whether statins have a preventive effect against HCC is unclear. A better understanding and management of metabolic factors may be beneficial to reduce the risk of HCC in patients with CLDs.

참고문헌 (99)

  1. Singal AG, "Epidemiology and surveillance for hepatocellular carcinoma : new trends", J Hepatol, 72, pp.250~261 (2020)
  2. Lombardi A, "Hepatocarcinoma : genetic and epigenetic features", Minerva Gastroenterol Dietol, 64, pp.14~27 (2018)
  3. McGlynn KA, "Global epidemiology of hepatocellular carcinoma : an emphasis on demographic and regional variability", Clin Liver Dis, 19, pp.223~238 (2015)
  4. Simon TG, "Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma : results from two prospective cohort studies", Hepatology, 67, pp.1797~1806 (2018)
  5. Jinjuvadia R, "The association between metabolic syndrome and hepatocellular carcinoma : systemic review and meta-analysis", J Clin Gastroenterol, 48, pp.172~177 (2014)
  6. Inoue M, "Impact of metabolic factors on subsequent cancer risk : results from a large-scale population-based cohort study in Japan", Eur J Cancer Prev, 18, pp.240~247 (2009)
  7. Makarova-Rusher OV, "Population attributable fractions of risk factors for hepatocellular carcinoma in the United States", Cancer, 122, pp.1757~1765 (2016)
  8. Ahlbom A, "Interaction : a word with two meanings creates confusion", Eur J Epidemiol, 20, pp.563~564 (2005)
  9. Andersson T, "Calculating measures of biological interaction", Eur J Epidemiol, 20, pp.575~579 (2005)
  10. Yi SW, "Risk factors for hepatocellular carcinoma by age, sex, and liver disorder status : a prospective cohort study in Korea", Cancer, 124, pp.2748~2757 (2018)
  11. Wang P, "Diabetes mellitus and risk of hepatocellular carcinoma : a systematic review and metaanalysis", Diabetes Metab Res Rev, 28, pp.109~122 (2012)
  12. Wang C, "Increased risk of hepatocellular carcinoma in patients with diabetes mellitus : a systematic review and meta-analysis of cohort studies", Int J Cancer, 130, pp.1639~1648 (2012)
  13. Cai C, "Association between hepatitis B virus infection and diabetes mellitus : a metaanalysis", Exp Ther Med, 10, pp.693~698 (2015)
  14. Mantovani A, "Non-alcoholic fatty liver disease and risk of incident diabetes mellitus : an updated meta-analysis of 501 022 adult individuals", Gut, 70, pp.962~969 (2021)
  15. Fabiani S, "Hepatitis C virus infection and development of type 2 diabetes mellitus : systematic review and meta-analysis of the literature", Rev Endocr Metab Disord, 19, pp.405~420 (2018)
  16. Kim K, "Association of fasting serum glucose level and type 2 diabetes with hepatocellular carcinoma in men with chronic hepatitis B infection : a large cohort study", Eur J Cancer, 102, pp.103~113 (2018)
  17. Campbell C, "Risk factors for the development of hepatocellular carcinoma(HCC)in chronic hepatitis B virus(HBV)infection : a systematic review and meta-analysis", J Viral Hepat, 28, pp.493~507 (2021)
  18. Hsu YC, "Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B", J Hepatol, 69, pp.278~285 (2018)
  19. Dyal HK, "Diabetes mellitus increases risk of hepatocellular carcinoma in chronic hepatitis C virus patients : a systematic review", Dig Dis Sci, 61, pp.636~645 (2016)
  20. Ioannou GN, "Differences in hepatocellular carcinoma risk, predictors and trends over time according to etiology of cirrhosis", PLoS One, 13, pp.e0204412~ (2018)
  21. Huang YW, "Increased risk of hepatocellular carcinoma in chronic hepatitis C patients with new onset diabetes : a nation-wide cohort study", Aliment Pharmacol Ther, 42, pp.902~911 (2015)
  22. Arase Y, "Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C", Hepatology, 57, pp.964~973 (2013)
  23. Ioannou GN, "Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLDrelated cirrhosis for risk stratification", J Hepatol, 71, pp.523~533 (2019)
  24. Yang JD, "Diabetes is associated with increased risk of hepatocellular carcinoma in patients with cirrhosis from nonalcoholic fatty liver disease", Hepatology, 71, pp.907~916 (2020)
  25. Kanwal F, "Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in nonalcoholic fatty liver disease", Hepatology, 71, pp.808~819 (2020)
  26. Bertot LC, "Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non-alcoholic fatty liver disease", Liver Int, 38, pp.1793~1802 (2018)
  27. Vilar-Gomez E, "Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease : a multi-national cohort study", Gastroenterology, 155, pp.443~457 (2018)
  28. Kawamura Y, "Large-scale long-term follow-up study of Japanese patients with non-alcoholic fatty liver disease for the onset of hepatocellular carcinoma", Am J Gastroenterol, 107, pp.253~261 (2012)
  29. Yang C, "Associations between diabetes mellitus and the risk of hepatocellular carcinoma in Asian individuals with hepatitis B and C infection : systematic review and a meta-analysis of cohort studies", Eur J Cancer Prev, 31, pp.107~116 (2022)
  30. Chen J, "Association of metabolic traits with occurrence of nonalcoholic fatty liver disease-related hepatocellular carcinoma : a systematic review and metaanalysis of longitudinal cohort studies", Saudi J Gastroenterol, 28, pp.92~100 (2022)
  31. Hum J, "improvement in insulin resistance after eradication of hepatitis C virus", Clin Liver Dis(Hoboken), 11, pp.73~76 (2018)
  32. Targher G, "The complex link between NAFLD and type 2 diabetes mellitus-mechanisms and treatments", Nat Rev Gastroenterol Hepatol, 18, pp.599~612 (2021)
  33. Chen CI, "Cancer risk in HBV patients with statin and metformin use: a populationbased cohort study", Medicine(Baltimore), 94, pp.e462~ (2015)
  34. Hsu YC, "Temporal trend and risk determinants of hepatocellular carcinoma in chronic hepatitis B patients on entecavir or tenofovir", J Viral Hepat, 25, pp.543~551 (2018)
  35. Yip TC, "Thiazolidinediones reduce the risk of hepatocellular carcinoma and hepatic events in diabetic patients with chronic hepatitis B", J Viral Hepat, 27, pp.904~914 (2020)
  36. Lee TY, "The occurrence of hepatocellular carcinoma in different risk stratifications of clinically noncirrhotic nonalcoholic fatty liver disease", Int J Cancer, 141, pp.1307~1314 (2017)
  37. Kramer JR, "Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease", Hepatology, 75, pp.1420~1428 (2022)
  38. Borena W, "Metabolic risk factors and primary liver cancer in a prospective study of 578, 700 adults", Int J Cancer, 131, pp.193~200 (2012)
  39. Samanic C, "Relation of body mass index to cancer risk in 362, 552 Swedish men", Cancer Causes Control, 17, pp.901~909 (2006)
  40. Chen Y, "Excess body weight and the risk of primary liver cancer : an updated meta-analysis of prospective studies", Eur J Cancer, 48, pp.2137~2145 (2012)
  41. Gupta A, "Obesity is independently associated with increased risk of hepatocellular cancer-related mortality : a systematic review and meta-analysis", Am J Clin Oncol, 41, pp.874~881 (2018)
  42. Parr CL, "Bodymass index and cancer mortality in the Asia-Pacific cohort studies collaboration : pooled analyses of 424, 519 participants", Lancet Oncol, 11, pp.741~752 (2010)
  43. Oh SW, "Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men : Korea national health insurance corporation study", J Clin Oncol, 23, pp.4742~4754 (2005)
  44. Batty GD, "Obesity and liver cancer mortality in Asia : the Asia Pacific cohort studies collaboration", Cancer Epidemiol, 33, pp.469~472 (2009)
  45. Yu MW, "Body-mass index and progression of hepatitis B : a population-based cohort study in men", J Clin Oncol, 26, pp.5576~5582 (2008)
  46. Fu SC, "Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with new onset diabetes : a nationwide cohort study", Aliment Pharmacol Ther, 41, pp.1200~1209 (2015)
  47. Loomba R, "Obesity and alcohol synergize to increase the risk of incident hepatocellular carcinoma in men", Clin Gastroenterol Hepatol, 8, pp.891~898 (2010)
  48. Chao LT, "Insulin, glucose and hepatocellular carcinoma risk in male hepatitis B carriers : results from 17-year follow-up of a population-based cohort", Carcinogenesis, 32, pp.876~881 (2011)
  49. Kim K, "Association of high body mass index and hepatocellular carcinoma in patients with chronic hepatitis B virus infection : a Korean population-based cohort study", JAMA Oncol, 4, pp.737~739 (2018)
  50. Veldt BJ, "Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus", Hepatology, 47, pp.1856~1862 (2008)
  51. Arano T, "Serum level of adiponectin and the risk of liver cancer development in chronic hepatitis C patients", Int J Cancer, 129, pp.2226~2235 (2011)
  52. Yang JD, "Diabetes mellitus heightens the risk of hepatocellular carcinoma except in patients with hepatitis C cirrhosis", Am J Gastroenterol, 111, pp.1573~1580 (2016)
  53. Lok AS, "Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease", Gastroenterology, 136, pp.138~148 (2009)
  54. McMahon BJ, "Infection with hepatitis C virus genotype 3 is an independent risk factor for end-stage liver disease, hepatocellular carcinoma, and liver-related death", Clin Gastroenterol Hepatol, 15, pp.431~437 (2017)
  55. Ohki T, "Obesity is an independent risk factor for hepatocellular carcinoma development in chronic hepatitis C patients", Clin Gastroenterol Hepatol, 6, pp.459~464 (2008)
  56. Hung CH, "Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferonbased antiviral therapy", Int J Cancer, 128, pp.2344~2352 (2011)
  57. Nair S, "Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis?", Hepatology, 36, pp.150~155 (2002)
  58. Pais R, "Nonalcoholic fatty liver disease increases the risk of hepatocellular carcinoma in patients with alcohol-associated cirrhosis awaiting liver transplants", Clin Gastroenterol Hepatol, 13, pp.992~999 (2015)
  59. Grimaudo S, "Association between PNPLA3 rs738409 C>G variant and liver-related outcomes in patients with nonalcoholic fatty liver disease", Clin Gastroenterol Hepatol, 18, pp.935~944 (2020)
  60. N’Kontchou G, "Risk factors for hepatocellular carcinoma in patients with alcoholic or viral C cirrhosis", Clin Gastroenterol Hepatol, 4, pp.1062~1068 (2006)
  61. Archambeaud I, "Risk factors for hepatocellular carcinoma in Caucasian patients with non-viral cirrhosis : the importance of prior obesity", Liver Int, 35, pp.1872~1876 (2015)
  62. Brichler S, "Non-virological factors are drivers of hepatocellular carcinoma in virosuppressed hepatitis B cirrhosis : results of ANRS CO12 CirVir cohort", J Viral Hepat, 26, pp.384~396 (2019)
  63. Ioannou GN, "Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis", Clin Gastroenterol Hepatol, 5, pp.938~945 (2007)[DOI]
  64. Ito T, "Serum nutritional markers as prognostic factors for hepatic and extrahepatic carcinogenesis in Japanese patients with nonalcoholic fatty liver disease", Nutr Cancer, 72, pp.884~891 (2020)
  65. Rahmani J, "Waist circumference and risk of liver cancer : a systematic review and meta-analysis of over 2 million cohort study participants", Liver Cancer, 9, pp.6~14 (2020)
  66. Fan R, "Association of central obesity with hepatocellular carcinoma in patients with chronic hepatitis B receiving antiviral therapy", Aliment Pharmacol Ther, 54, pp.329~338 (2021)
  67. 이재민, "Obesity and hepatocellular carcinoma in patients receiving entecavir for chronic hepatitis B", Clinical and Molecular Hepatology, 22(3), pp.339~349 (2016), 대한간학회
  68. Osaki Y, "Metabolic syndrome and incidence of liver and breast cancers in Japan", Cancer Epidemiol, 36, pp.141~147 (2012)
  69. Häggström C, "Linear age-course effects on the associations between body mass index, triglycerides, and female breast and male liver cancer risk : an internal replication study of 800, 000 individuals", Int J Cancer, 146, pp.58~67 (2020)
  70. Cho Y, "Association between lipid profiles and the incidence of hepatocellular carcinoma: a nationwide population-based study", Cancers(Basel), 13, pp.1599~ (2021)
  71. Yi SW, "Higher cholesterol levels, not statin use, are associated with a lower risk of hepatocellular carcinoma", Br J Cancer, 122, pp.630~633 (2020)
  72. Sinn DH, "Risk of hepatocellular carcinoma in individuals without traditional risk factors : development and validation of a novel risk score", Int J Epidemiol, 49, pp.1562~1571 (2020)
  73. Nderitu P, "The association between individual metabolic syndrome components, primary liver cancer and cirrhosis : a study in the Swedish AMORIS cohort", Int J Cancer, 141, pp.1148~1160 (2017)
  74. Chiang CH, "Opposite association between diabetes, dyslipidemia, and hepatocellular carcinoma mortality in the middle-aged and elderly", Hepatology, 59, pp.2207~2215 (2014)
  75. Goh MJ, "Statin use and the risk of hepatocellular carcinoma in patients with chronic hepatitis B", Hepatology, 71, pp.2023~2032 (2020)
  76. Wu CY, "Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B : a nationwide cohort study", Gastroenterology, 147, pp.143~151 (2014)
  77. Tan Y, "The influence of metabolic syndrome on the risk of hepatocellular carcinoma in patients with chronic hepatitis B infection in mainland China", Cancer Epidemiol Biomarkers Prev, 28, pp.2038~2046 (2019)
  78. Arain SQ, "Serum lipid profile as a marker of liver impairment in hepatitis B cirrhosis patients", Lipids Health Dis, 16, pp.51~ (2017)
  79. Vere CC, "Lipid serum profile in patients with viral liver cirrhosis", Med Princ Pract, 21, pp.566~568 (2012)
  80. Jiang J, "Influence of liver cancer on lipid and lipoprotein metabolism", Lipids Health Dis, 5, pp.4~ (2006)
  81. Chrostek L, "The effect of the severity of liver cirrhosis on the level of lipids and lipoproteins", Clin Exp Med, 14, pp.417~421 (2014)
  82. Janičko M, "Serum cholesterol is a significant and independent mortality predictor in liver cirrhosis patients", Ann Hepatol, 12, pp.581~587 (2013)
  83. Ghadir MR, "The relationship between lipid profile and severity of liver damage in cirrhotic patients", Hepat Mon, 10, pp.285~288 (2010)
  84. Bassani L, "Lipid profile of cirrhotic patients and its association with prognostic scores : a cross-sectional study", Arq Gastroenterol, 52, pp.210~215 (2015)
  85. Tauseef A, "Correlation of fasting lipid profile in patients with chronic liver disease : a descriptive cross-sectional study in Tertiary Care Hospital", Cureus, 12, pp.e11019~ (2020)
  86. Choe JW, "Influence of metabolic syndrome on cancer risk in HBV carriers : a nationwide population based study using the national health insurance service database", J Clin Med, 10, pp.2401~ (2021)
  87. Tsan YT, "Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection", J Clin Oncol, 30, pp.623~630 (2012)
  88. Hsiang JC, "Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population : a propensity score landmark analysis", J Hepatol, 63, pp.1190~1197 (2015)
  89. Tsan YT, "Statins and the risk of hepatocellular carcinoma in patients with hepatitis C virus infection", J Clin Oncol, 31, pp.1514~1521 (2013)
  90. Butt AA, "Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons : results from ERCHIVES", Hepatology, 62, pp.365~374 (2015)
  91. Mohanty A, "Statins are associated with a decreased risk of decompensation and death in veterans with hepatitis C-related compensated cirrhosis", Gastroenterology, 150, pp.430~440 (2016)
  92. Simon TG, "Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus : results from ERCHIVES", Hepatology, 64, pp.47~57 (2016)
  93. Li X, "Statin and the risk of hepatocellular carcinoma in patients with hepatitis B virus or hepatitis C virus infection : a meta-analysis", BMC Gastroenterol, 20, pp.98~ (2020)
  94. Wong YJ, "Efficacy and safety of statin for hepatocellular carcinoma prevention among chronic liver disease patients : a systematic review and meta-analysis", J Clin Gastroenterol, 55, pp.615~623 (2021)
  95. Friedman GD, "Statins and reduced risk of liver cancer : evidence for confounding", J Natl Cancer Inst (2016)
  96. Jeong GH, "Effect of statin on cancer incidence : an umbrella systematic review and meta-analysis", J Clin Med, 8, pp.819~ (2019)
  97. Cholesterol Treatment Trialists’(CTT)Collaboration, "Lack of effect of lowering LDL cholesterol on cancer : meta-analysis of individual data from 175, 000 people in 27 randomised trials of statin therapy", PLoS One, 7, pp.e29849~ (2012)
  98. Yu MW, "Influence of metabolic risk factors on risk of hepatocellular carcinoma and liver-related death in men with chronic hepatitis B : a large cohort study", Gastroenterology, 153, pp.1006~1017 (2017)
  99. Yi SW, "Sex-age-specific association of body mass index with all-cause mortality among 12. 8 million Korean adults : a prospective cohort study", Int J Epidemiol, 44, pp.1696~1705 (2015)

관련 논문AI추천

Development and prognosis of hepatocellular carcinoma in patients with diabetesRyosuke Tateishi, Takuma Nakatsuka대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제1호Diabetes and Risk of Hepatocellular Carcinoma in Cirrhosis Patients with Nonalcoholic Fatty Liver DiseaseHuang Daniel Q., Lin Ting-Yi, Noureddin Mazen, Teng Pai-Chi, Yang Ju Dong거트앤리버 소화기연관학회협의회 · Gut and Liver2023 · 제17권 제1호Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysisAlessandro Vitale, Anjiya Shaikh, Beom Kyung Kim, Cameron Gofton, George Cholankeril, Gianluca Svegliati-Baroni, Guy D. Eslick, Harry Crane, Jacob George, Jian-Hong Zhong, Mark Cheah, Mi Na Kim, Sang Hoon Ahn, Simone I Strasser대한간학회 · Clinical and Molecular Hepatology2024 · 제30권 제3호Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analoguesAdrian Gadano, Akito Nozaki, Chao Wu, Cheng-Hao Tseng, Chia-Yen Dai, Chung-Feng Huang, Dae Won Jun, Daniel Q. Huang, Eileen Yoon, Gi-Ae Kim, Haruki Uojima, Hidenori Toyoda, Hirokazu Takahashi, Hiroshi Abe, Huy Trinh, Hyunwoo Oh, Jang Han Jung, Jee-Fu Huang, Jie Li, Joanne Kimiko Liu, Kaori Inoue, Keigo Kawashima, Koichi Takaguchi, Kunihiko Tsuji, Masanori Atsukawa, Masaru Enomoto, Masatoshi Ishigami, Mindie H. Nguyen, Ming-Lung Yu, Ming-Lun Yeh, Norio Itokawa, Pei-Chien Tsai, Philip Vutien, Ramsey Cheung, Ritsuzo Kozuka, Rui Huang, Sang Bong Ahn, Sebastián Marciano, Soung Won Jeong, Sung Eun Kim, Takashi Honda, Tomonori Senoh, Toru Ishikawa, Tsunamasa Watanabe, Wan-Long Chuang, Yao-Chun Hsu, Yasuhito Tanaka대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제3호Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B김광일, 김미나, 전영은, 하연정, 황성규, Hana Park, Joo Ho Lee, Kyu Sung Rim, Soo-Hwan Kim, Yun Bin Lee대한간학회 · Clinical and Molecular Hepatology2019 · 제25권 제1호Preventive strategy for nonalcoholic fatty liver disease-related hepatocellular carcinomaBo Hyun Kim, Joong-Won Park, Yuri Cho대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제2호

이 간행물의 다른 논문 (24건)

2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinomaNational Cancer Center (NCC) Korea, Korean Liver Cancer Association (KLCA)pp. 583-705The emerging roles of extracellular vesicles as intercellular messengers in liver physiology and pathologyJong-Hoon Kim, Youngseok Leepp. 706-724Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative reviewGiovanni Targher, Ming-Hua Zheng, Jing Xu, Lei Miao, Christopher D Byrnepp. 725-738Prediction models of hepatocellular carcinoma recurrence after liver transplantation: A comprehensive reviewJong Man Kim, Sang Jin Kimpp. 739-753Deep learning-based prediction of molecular cancer biomarkers from tissue slides: A new tool for precision oncologyHyun-Jong Jang, Sung Hak Leepp. 754-772
원문 보기